Evidence map›Paper›PMID 42840422›Full record

ArticleMolecular therapy. Nucleic acids2026

Aptamer-guided delivery of miR-126 suppresses glioblastoma stem-like cell invasion and tumor progression.

Giorgia Castellani, Mariachiara Buccarelli, Alessandra Affinito, Gabriele De Luca, Ramona Ilari, Francesca Pedini, Alessandra Di Giamberardino, Mariagiovanna Ballato, Gabriele Ricciardi, Martina Offi and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Giorgia CastellaniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Mariachiara BuccarelliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Alessandra AffinitoIRCCS SYNLAB SDN, 80143 Naples, Italy.
Gabriele De LucaDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Ramona IlariDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Francesca PediniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Alessandra Di GiamberardinoDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Mariagiovanna BallatoDepartment of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98122 Messina, Italy.
Gabriele RicciardiDepartment of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98122 Messina, Italy.
Martina OffiDepartment of Neuroscience, Catholic University School of Medicine, 00168 Rome, Italy.
Cristiana MollinariDepartment of Neuroscience, Istituto Superiore di Sanità, 00161 Rome, Italy.
Nadia FelliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Alessandra BoeCore Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.
Giovanna MarzialiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Mauro BiffoniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.
Maria CaffoBiomedical and Dental Sciences and Morphofunctional Imaging, Unit of Neurosurgery, University of Messina, 98122 Messina, Italy.
Gerolama CondorelliDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Maurizio MartiniDepartment of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98122 Messina, Italy.
Quintino Giorgio D'AlessandrisDepartment of Neurosurgery, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Lucia Ricci-VitianiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma, IDH-wildtype (GBM) is the most common and aggressive primary brain tumor in adults, with a median overall survival of 15-18 months. New therapeutic targets are needed to improve patients' prognosis. Due to their powerful regulatory capabilities, miRNAs could be possible candidate targets. MiR-126 is considered a tumor suppressor in several cancers, including GBM. In a previous study, we found that the infiltrative shift observed in response to bevacizumab in a GBM mouse model, induced a high miR-126 downregulation, confirming its tumor-suppressor function, exerted by inhibiting growth and angiogenesis. Here, we either stably restored miR-126 expression in GBM stem-like cells by transduction or transiently delivered it through an A40s aptamer-based conjugate. Both interventions led to an overall impairment of tumorigenic properties. Notably,

Indexed as

aptamersglioblastomaglioblastoma stem-like cellsLΑΤ1miRNA-126MT: Special Issue: innovations in aptamer technologyPLXNB2SPRED1

Identifiers

PMID42840422
PMCPMC13639097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.